中德临床肿瘤学杂志（英文版）2008，Vol.7Issue(7)：400-403,4.
西妥昔单抗联合化疗在结直肠癌中的回顾性研究
Retrospective study of cetuximab in combination with chemotherapy for patients with colorectal cancer
Zhihao Lu 1Xiaotian Zhang 1Lin Shen 1Xiaodong Zhang 1Jie Li 1Zhongtao Zhang2
作者信息
- 1. Department of GI Oncology,Peking University,School of Oncology,Beijing Cancer Hospital & Institute,Beijing 100036,China
- 2. Department of General Surgery,Beijing Youyi Hospital,Beijing 100036,China
- 折叠
摘要
Abstract
Objective:To evaluate the efficacy and safety of cetuximab combined with chemotherapy in colorectal cancer (CRC).Methods:35 cases of CRC were retrospectively analyzed.Efficacy and adverse events were observed.Results:29 cases of CRC were evaluated by RECIST criteria,showing 7 PR (partial response,24.1%) and 15 SD (stable disease,51.8%),disease control rate (DC) was 75.9%.Subgroup analysis showed response rate (RR) of 36.4% and DC of 91% in the 1st line therapy,RR of 20% and DC of 70% in the 2rid line therapy,RR of 12.5% and DC of 62.5% in heavily pre-treated cases.Rash appeared in 74.3% of patients (grade 3 was 8.6%),and the severity was relevant with disease control rate (DC).Neutropenia of grade 3/4 was 14.3%,and infusion related reaction (IRR) of grade 3 happened in 1 case (2.9%).Conclusion:Cetuximab combined with chemotherapy is safe and effective for patients with metastatic colorectal cancer.The combination therapy shows high DC,especially in 1st line therapy.Severity of rash may predict efficacy.关键词
cetuximab/chemotherapy/colorectal cancer (CRC)/efficacyKey words
cetuximab/chemotherapy/colorectal cancer (CRC)/efficacy分类
医药卫生引用本文复制引用
Zhihao Lu,Xiaotian Zhang,Lin Shen,Xiaodong Zhang,Jie Li,Zhongtao Zhang..西妥昔单抗联合化疗在结直肠癌中的回顾性研究[J].中德临床肿瘤学杂志（英文版）,2008,7(7):400-403,4.
